Deferred Systemic Therapy Reasonable for Selected Renal Cell Carcinoma Patients

Deferred systemic therapy is a reasonable option for selected patients with metastatic renal cell carcinoma (mRCC), according to researchers. This approach may offer patients a better quality of life without negatively affecting survival.
Investigators at Duke University in Durham, NC, led by Daniel J. George, MD, reviewed data from 60 patients with mRCC who did not receive systemic therapy within the first year after diagnosis.1
Patients had a median age of 61.2, and their median duration from diagnosis of localized RCC to development of mRCC was 41.9 months.
Of these patients, 36 (60%) were managed with surgical metastasectomy alone, 7 patients (12%) received multiple local treatment modalities, 8 patients (13%) underwent active surveillance, 4 patients (7%) were managed supportively, and 5 patients (8%) were categorized as “other.”
The cohort had a median follow-up of 52.9 months. The 3-year survival was 83% overall and 94% for patients who underwent surgical metastasectomy as the initial management strategy.
At 3 years, 49% of patients had no evidence of disease and 19% had died or been transitioned to hospice. The 5-year survival rate was 59%, and 24% still had no evidence of disease.
“Although the new targeted therapies for mRCC are better tolerated than systemic chemotherapies, they still have serious side effects,” the authors wrote. “Therefore, a strategy of delaying therapy may result in significant quality of life gains for these patients.”
In a discussion of study limitations, Dr. George’s group pointed out that their cohort included only patients treated at a large academic medical center, so their sample may not be representative of all patients with mRCC or clinical environments because of sample bias and self-selection bias.
Mounting Evidence
The study adds to a growing body of evidence suggesting that deferred systemic therapy may be an attractive option for selected patients.1
Investigators at the University of Ulsan College of Medicine in Seoul, South Korea, studied 58 patients with asymptomatic or minimally symptomatic mRCC placed on active surveillance.2
After a median follow-up of 31.4 months, the median time to progression (the primary endpoint of the study) was 12.4 months, and the median overall survival was not reached.
 
Read the full article HERE